Reviva Pharmaceuticals Holdings, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to advancing novel therapeutic solutions. The company strives to identify, develop, and commercialize treatments that address significant unmet medical needs across various therapeutic areas, including disorders of the central nervous system, respiratory conditions, cardiovascular issues, metabolic syndromes, and inflammatory diseases. Its primary investigational drug, RP5063, is currently undergoing Phase III clinical trials for the treatment of schizophrenia.